RT Journal Article
SR Electronic
T1 Dissemination and co-circulation of SARS-CoV2 subclades exhibiting enhanced transmission associated with increased mortality in Western Europe and the United States
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.13.20152959
DO 10.1101/2020.07.13.20152959
A1 Hu, Yuan
A1 Riley, Lee W.
YR 2020
UL http://medrxiv.org/content/early/2020/07/15/2020.07.13.20152959.abstract
AB Mechanisms underlying the acute respiratory distress syndrome (ARDS)-like clinical manifestations leading to deaths in patients who develop COVID-19 remain uncharacterized. While multiple factors could influence these clinical outcomes, we explored if differences in transmissibility and pathogenicity of SARS-CoV2 variants could contribute to these terminal clinical consequences of COVID-19. We analyzed 34,412 SARS-CoV2 sequences deposited in the Global Initiative for Sharing All Influenza Data (GISAID) SARS-CoV2 sequence database to determine if regional differences in circulating strain variants correlated with increased mortality in Europe, the United States, and California. We found two subclades descending from the Wuhan HU-1 strain that rapidly became dominant in Western Europe and the United States. These variants contained nonsynonymous nucleotide mutations in the Orf1ab segment encoding RNA-dependent RNA polymerase (C14408T), the spike protein gene (A23403G), and Orf1a (G25563T), which resulted in non-conservative amino acid substitutions P323L, D614G, and Q57H, respectively. In Western Europe, the A23403G-C14408T subclade dominated, while in the US, the A23403G-C14408T-G25563T mutant became the dominant strain in New York and parts of California. The high cumulative frequencies of both subclades showed inconsistent but significant association with high cumulative CFRs in some of the regions. When the frequencies of the subclades were analyzed by their 7-day moving averages across each epidemic, we found co-circulation of both subclades to temporally correlate with peak mortality periods. We postulate that in areas with high numbers of these co-circulating subclades, a person may get serially infected. The second infection may trigger a hyperinflammatory response similar to the antibody-dependent enhancement (ADE) response, which could explain the ARDS-like manifestations observed in people with co-morbidity, who may not mount sufficient levels of neutralizing antibodies against the first infection. Further studies are necessary but the implication of such a mechanism will need to be considered for all current COVID-19 vaccine designs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes1. The number of SARS-CoV2 genome sequences from each country in the GISAID database that were included in the analyses are provided in the Supplementary material Table 1. 2. Calculations of Odds Ratio and 95% CI to assess association of the dominant subclades with high case-fatality rates (CFRs) are provided in Supplementary material Tables 2A-C. 3. URLs of the sources of data regarding co-factors that may affect CFRs are shown under Table in the manucript. https://www.worldometers.info/coronavirus/ https://www.gisaid.org/ https://www.sccgov.org/sites/covid19/Pages/dashboard-cases.aspx https://www.nbcnews.com/health/health-news/here-are-stay-home-orders-across-country-n1168736 https://www.cia.gov/library/publications/the-world-factbook/fields/343.html https://worldpopulationreview.com/ https://www.diabetesatlas.org/upload/resources/2019/IDF_Atlas_9th_Edition_2019.pdf https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html# https://www.who.int/nmh/countries/ https://gis.cdc.gov/grasp/diabetes/DiabetesAtlas.html#